GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

NCT07221214 on ClinicalTrials.gov · last registry update 2026-05-26

Recruiting now, toward 200 participants. Due to report 31 October 2029, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Average drinks/week past 30 days at 3 months. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Vanderbilt University Medical Center
Sponsor type: Other
Enrollment: 200
Started: 2026-04-17
Primary completion: 2029-10-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Average drinks/week past 30 days at 3 months

Conditions studied

HIV · Alcohol · Smoking Cigarette · Cardiovascular Disease Prevention

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.